Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sanyrene (also marketed as Corpitol) is a topical lipid-based formulation developed by Laboratoires Urgo for the prevention and treatment of skin integrity issues. Its primary component is Corpitolinol 60, a complex of hyperoxygenated fatty acids (predominantly linoleic acid) enriched with Vitamin E. The mechanism of action involves the attenuation of cutaneous inflammation by competing with arachidonic acid and inhibiting the production of proinflammatory eicosanoids. Additionally, it reinforces the skin's hydrolipidic film and improves local tissue oxygenation. It is clinically indicated for the prevention of pressure ulcers (pressure injuries), the treatment of erythema, and the prophylaxis of radiation-induced dermatitis in oncology patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sanyrene.